Letter to the Editor

Congenital hypothyroidism as the initial presentation of pendred syndrome associated with mutated IVS7-2A > G in SLC26A4 gene in a Taiwanese neonate

Pendred syndrome (PS) is one of the common syndromic forms of hereditary sensorineural hearing loss. The SLC26A4/PDS gene, which encodes an anion transporter, known as pendrin, is the cause of PS. The classical symptoms include sensorineural hearing impairment, associated with an enlarged vestibular aqueduct (EVA), and goiter due to an abnormal organification of iodide. Thyroid function in PS is phenotypically variable, and not all affected individuals develop goiter. Here, we presented a case where neonatal screening revealed congenital hypothyroidism (CH), which later manifested language delay, while genetic investigation confirmed the diagnosis of PS.

A full-term female neonate was uneventfully born to Taiwanese parents who were not consanguineous. Her initial level of thyroid-stimulating hormone was up to 227 uU/ml (normal range: 0.25–4.00 uU/ml), T3 122.56 ng/dl (78–182 ng/dl), and T4 6.17 ug/dl (5–12 ug/dl), according to neonatal screening and confirmatory results. Physical examination did not reveal goiter, and a Tc-99 m pertechnetate thyroid scan showed a normal appearance of thyroid in paratracheal space (Supplementary Fig. 1). With a highly elevated TSH level suggesting a diagnosis of CH, we expedited treatment with levothyroxine to maximize her potential for normal development according to the updated consensus guidelines. Despite her growth curve and developmental milestones attained initially within a normal range during treatment with levothyroxine to maximize her potential for normal development according to the updated consensus guidelines, she was found to be delayed in speech at the age of 18 months. Further auditory examination found bilateral sensorineural hearing impairment with a threshold around 100 db, although her neonatal screening and confirmatory results suggested the deletion of the entire exon 8, leading to a frameshift and premature termination of translation. However, phenotypic presentations of this mutation are variable but rarely seen in screening-detected CH.

From a clinical perspective, CH patients can achieve milestones without delay if they are treated early and appropriately once upon diagnosis by neonatal screening. Genetic diagnosis for CH is not usually sought in practice. The diagnosis of PS can sometimes be delayed such as in our case who passed the initial neonatal hearing screening and manifested slow language development later in life. A perchlorate discharge test may be helpful to identify a defective organification of iodide but is infrequently used to differentiate the etiology of thyroid dyshormonogenesis, because it cannot suggest the specific underlying molecular

https://doi.org/10.1016/j.pedneo.2022.06.008
1875-9572/© 2022, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Thus, a genetic study of SLC26A4 gene may be indicated to confirm the diagnosis of PS in CH patients that are also hearing-impaired, because non-goitrous hypothyroidism can be a potential manifestation of PS.

As of yet, CH in PS has been sporadic, despite that nearly 50% of PS patients may have abnormal thyroid function, ranging from subclinical to overt hypothyroidism. On the contrary, a survey of PS among a cohort of 197 Caucasians with hypothyroidism only found two patients to be compound heterozygotes for SLC26A4 mutations and thus concluded that PS is rarely detected by neonatal screening for CH. In another cohort of 192 Chinese CH patients, none was found to be compatible with PS, although eight cases were heterozygous for SLC26A4 mutations. Adding to current literature, our report highlights that vigilant monitoring of child development is warranted in CH patients, irrespective of their thyroid function status during treatment.

Declaration of competing interest

The authors have no conflicts of interest relevant to this article.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.pedneo.2022.06.008.

References


Sun-Mei Chung
School of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Yu-Wen Pan
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Yi-Shan Tsai
Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Clinical Innovation and Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng-Kung University, Tainan 70457, Taiwan

Meng-Che Tsai*
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Department of Genomic Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

*Corresponding author. Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University 138 Sheng-Li Road, Tainan 704, Taiwan.

E-mail address: ache93@yahoo.com.tw (M.-C. Tsai)

Oct 21, 2021